Discovery of cancer genes through interrogation of genomic dosage is one of the major approaches in cancer research. In this study, we report that phosphodiesterase subtype 4D (PDE4D) gene was homozygously deleted in 198 cases of 5,569 primary solid tumors (3.56%), with most being internal microdeletions. Unexpectedly, the microdeletions did not result in loss of their gene products. Screening PDE4D expression in 11 different types of primary tumor samples (n = 165) with immunohistochemistry staining revealed that its protein levels were up-regulated compared with corresponding nontransformed tissues. Importantly, depletion of endogenous PDE4D with three independent shRNAs caused apoptosis and growth inhibition in multiple types of cancer cells, including breast, lung, ovary, endometrium, gastric, and melanoma, which could be rescued by reexpression of PDE4D. We further showed that antitumor events triggered by PDE4D suppression were lineage-dependently associated with Bcl-2 interacting mediator of cell death (BIM) induction and microphthalmia-associated transcription factor (MITF) downregulation. Furthermore, ectopic expression of the PDE4D short isoform, PDE4D2, enhanced the proliferation of cancer cells both in vitro and in vivo. Moreover, treatment of cancer cells with a unique specific PDE4D inhibitor, 26B, triggered massive cell death and growth retardation. Notably, these antineoplastic effects induced by either shRNAs or small molecule occurred preferentially in cancer cells but not in nonmalignant epithelial cells. These results suggest that although targeted by genomic homozygous microdeletions, PDE4D functions as a tumor-promoting factor and represents a unique targetable enzyme of cancer cells.
Discovery of cancer genes through interrogation of genomic dosage is one of the major approaches in cancer research. In this study, we report that phosphodiesterase subtype 4D (PDE4D) gene was homozygously deleted in 198 cases of 5,569 primary solid tumors (3.56%), with most being internal microdeletions. Unexpectedly, the microdeletions did not result in loss of their gene products. Screening PDE4D expression in 11 different types of primary tumor samples (n = 165) with immunohistochemistry staining revealed that its protein levels were up-regulated compared with corresponding nontransformed tissues. Importantly, depletion of endogenous PDE4D with three independent shRNAs caused apoptosis and growth inhibition in multiple types of cancer cells, including breast, lung, ovary, endometrium, gastric, and melanoma, which could be rescued by reexpression of PDE4D. We further showed that antitumor events triggered by PDE4D suppression were lineage-dependently associated with Bcl-2 interacting mediator of cell death (BIM) induction and microphthalmia-associated transcription factor (MITF) downregulation. Furthermore, ectopic expression of the PDE4D short isoform, PDE4D2, enhanced the proliferation of cancer cells both in vitro and in vivo. Moreover, treatment of cancer cells with a unique specific PDE4D inhibitor, 26B, triggered massive cell death and growth retardation. Notably, these antineoplastic effects induced by either shRNAs or small molecule occurred preferentially in cancer cells but not in nonmalignant epithelial cells. These results suggest that although targeted by genomic homozygous microdeletions, PDE4D functions as a tumor-promoting factor and represents a unique targetable enzyme of cancer cells.
T he phosphodiesterases (PDEs) are metallohydrolases, which degrade the secondary messengers, adenosine and guanosine 3′,5′-cyclic monophosphates (cAMP and cGMP, respectively) (1, 2) . The PDEs are grouped into 11 families (PDE1-11) according to their substrate specificities, subcellular distributions, and amino acid sequences (3, 4) . Multiple types of human tumor cells predominantly express PDE4 as major regulators of cAMP-hydrolyzing activity (5) . Of note, PDE4 inhibitors (PDE4i) were reported to have antineoplastic functions in several human malignancies including leukemia, colon cancer, and glioma (6) (7) (8) (9) (10) .
Phosphodiesterase subtype 4D (PDE4D) belongs to PDE4 subfamilies (A, B, C, and D). PDE4D gene (human locus 5p12.1) encodes a complex of transcript variants generated by both multiple promoter use and alternative mRNA splicing. PDE4D consists of at least nine protein isoforms that all possess the phosphodiesterase catalytic domain in the carboxyl terminus and are categorized into one of the so-called "long," "short," and "supershort" forms (reviewed in ref. 11). Interestingly, a previous study using a sleeping beauty transposon-based screen suggested that PDE4D might function as a proliferation promoting factor in prostate cancers (12) . Very recently, Pullamsetti et al. found that cross-talk that occurred between PDE4 and hypoxia induciblefactor signaling might promote angiogenesis in lung cancer (13) . However, the tumor-specific alterations in PDE4D genome and function are not well elucidated.
Homozygous deletions in cancer genomes occur at recessive cancer genes, conferring clonal growth advantage. This type of deletions is also found within fragile sites and reflects an increased local rate of DNA breakage with no cancer-associated biological consequences. To date, the implications of most homozygous deletions in cancer genomes remain elusive. In the present study, we identified homozygous microdeletions in the human PDE4D gene locus in primary tumors, as well as in established cancer cells of diverse origins. Unexpectedly, PDE4D mRNA and proteins were not abrogated, i.e., deletions did not result in inactivation of PDE4D. Moreover, we found that PDE4D protein expression levels were elevated in multiple types of cancers. Further investigations revealed that PDE4D contributed to the proliferation and prosurvival of tumor cells.
Results

Identification of Genomic and Expression Abnormalities in Human
PDE4D Gene. DNA from 55 triple negative breast cancer (TNBC) individuals were examined by SNP-Chip assay for genomic abnormalities (SI Appendix, Fig. S1 ). Homozygous microdeletions in PDE4D (Chr5: q11.2-q12.1) were observed in one patient [triple negative breast tumor (TNT)-18, validation shown in SI Appendix, Fig. S3A] . This prompted us to analyze somatic copy number alterations of 5,569 solid tumor primary specimens from The Cancer Genome Atlas (TCGA) projects as well as TumorScape (14) . We identified homozygous deletions of PDE4D in 198 samples (3.56%). Notably, 81.3% (161/198) of the deletions affected only the intragenic regions of PDE4D, without removing the whole gene (Fig. 1) . We further interrogated PDE4D homozygous deletions in established cancer cell lines with in-house SNP-Chip data (SI Appendix, Fig. S2 ), as well as those from the Wellcome Trust Sanger Institute Cancer Genome Project. Internal homozygous microdeletions of PDE4D were evident in an additional nine different tumor cell lines, including breast, lung, and gastric cancers (SI Appendix, Fig. S3 A and B) . We then examined the expression of PDE4D, first at the transcriptional level and found that most of the PDE4D-microdeleted samples still expressed PDE4D messenger RNAs ( Fig.  2A) . Different use of PDE4D isoforms was noted in different cell lines ( Fig. 2A) . Importantly, analysis of a large number of cases from four different cancer datasets revealed that tumors with PDE4D deletions have comparable abundance of PDE4D mRNA expression (Fig. 2C) . At the translational level, all of the cell lines harboring PDE4D microdeletions expressed appreciable levels of PDE4D proteins compared with PDE4D-unaffected cells, albeit in different isoforms as evidenced by reduced sizes on SDS/PAGE ( Fig. 2B and SI Appendix, Fig. S3C ).
We next examined the expression of PDE4D proteins in a wide spectrum of primary tumor specimens using immunohistochemistry. Again surprisingly, PDE4D proteins were detectable in most of the cancer types tested, with elevated expression in tumors compared with adjacent normal tissues including melanoma, ovarian, endometrial, and gastric cancers ( Fig. 3A and SI Appendix, Table S5 ). Analysis of survival data from TCGA projects showed that high PDE4D mRNA expression was associated with worse prognosis in both an endometrium cancer cohort and a head and neck squamous cell carcinoma cohort of patients but not in those with either ovarian cancers or breast cancers ( Fig. 3B and SI Appendix, Fig. S4 ).
Depletion of PDE4D Triggered Apoptosis and Suppressed Cell Growth in a Panel of Human Cancer Cells. Based on the observations that: (i) the homozygous internal deletions in PDE4D gene did not result in loss of either mRNA or protein expression levels and (ii) PDE4D proteins levels were up-regulated in several different types of tumors, we hypothesized that PDE4D gene products are necessary for promoting and/or maintaining the transformed phenotype of the cancer cells. To study the cancer-specific function of PDE4D, cell line models representing tumors showing elevated expression level of PDE4D proteins from our immunohistochemistry data were selected, namely melanoma, ovarian, endometrial, and gastric cancers. We also included breast cell line (MB-231) because they are triple negative breast cancer cells and our initial observation was derived from this type of cancer. Lung cancer cells (A549) were further investigated because PDE4A and PDE4D have been associated with lung cancer (13) . We first depleted endogenous PDE4D mRNA and protein expression by shRNA-mediated knockdown. All three shRNAs targeted the carboxy terminus of PDE4D, leading to the inhibition of all known human PDE4D gene transcripts. Notably, depletion of PDE4D induced apoptosis within 72-96 h after infection of lentiviral particles as measured by both annexin-V exposure and cleavage of Poly ADP-ribose polymerase 1 (PARP), regardless of the status of PDE4D genomic microdeletions ( Fig. 4 A and B and SI Appendix, Fig. S5A ). Cells became round, refractile, and misformed upon PDE4D knockdown (SI Appendix, Fig. S5B ). In addition, shRNAs caused growth retardation of all cell lines tested ( Fig. 4C and SI Appendix, Fig. S5C ). These results strongly suggest that PDE4D is indispensable for maintaining cancer cell viability.
To confirm that the apoptosis triggered by shPDE4Ds was specifically due to the depletion of PDE4D rather than off-target effects, restoration of PDE4D expression experiments were performed. We took advantage of the fact that one of the three shPDE4Ds (shPDE4D-a) was designed to target the 3′ untranslated region (3′-UTR) of the PDE4D transcripts, and our ectopic expression vectors did not contain this region. We first stably expressed ectopic PDE4D2 (supershort form of human PDE4D transcripts) into MB-231 cells and then infected these cells with shPDE4D-a lentiviral particles. The shPDE4D-a powerfully suppressed the expression of endogenous but not exogenous PDE4D (Fig. 4D) . Importantly, flow cytometry (FCM) and cell morphology analysis revealed that PDE4D2 restoration efficiently rescued MB-231 from apoptosis induced by depletion of PDE4D ( Fig. 4E and SI Appendix, Fig. S5F ). Similar results were obtained with melanoma M368 cells (SI Appendix, Fig. S6 ). Furthermore, in A2008 ovarian cancer cells, which expressed undetectable endogenous PDE4D proteins, shPDE4D-a neither caused apoptosis nor inhibited cell proliferation (SI Appendix, Fig. S5D ).
The findings that PDE4D proteins were elevated in several types of cancers prompted us to ask whether the antiproliferative effects induced by PDE4D depletion were specific to cancer cells. To this end, nonmalignant mammary epithelial cells (MCF-10A) were transduced with shPDE4D-a. Importantly, no detectable effect on either apoptosis or growth rate was caused by suppression of PDE4D expression (SI Appendix, Fig. S5E ).
Bcl-2 interacting mediator of cell death (BIM) Contributes to shPDE4D-Induced Apoptosis. We next investigated the molecular mechanisms governing shPDE4D-promoted antitumor effects. As expected, Fig. 1 . Intragenic PDE4D microdeletions in human cancers. Integrative Genomics Viewer (IGV) heatmap of PDE4D copy number data for various cancer samples from TCGA as well as TumorScape. Copy number value for homozygous deletions (< −0.79) is calculated based on the presumptions that: (i) loss of both alleles was present in >70% cancer cell populations, and (ii) normal cell contamination was <25%. Lung SCC, lung squamous cell carcinoma; HNSCC, head and neck squamous cell carcinoma; ESCC, esophageal squamous cell carcinoma; HCC, hepatocellular carcinoma; RCC, renal cell carcinoma; NSCLC, nonsmall cell lung cancer. M, microdeletions; W, deletions affected whole PDE4D.
phosphorylation of cAMP responsive element binding protein (phospho-CREB) was enhanced in PDE4D-depleted cells, indicating induction of cAMP-mediated signaling (Fig. 5A) . Western blotting analysis suggested that the mitochondrial-associated apoptosis pathway was activated in shPDE4D-infected cells. Examination of Bcl-2 Homology 3 (BH3)-containing family members revealed that the proapoptotic protein BIM was markedly elevated upon PDE4D depletion in both A549 and MB-231 cells (Fig. 5A ). Increased expression of BIM was previously reported as one of the mechanisms for cAMP-induced apoptosis of immature T cells (15) . To test whether BIM is a critical determinant of shPDE4D-promoted apoptosis, we stably silenced BIM (shBIM) and assessed the impact of BIMdepletion on shPDE4D-induced cell apoptosis. As shown in Fig.  5B , stable silencing of BIM inhibited the up-regulation of BIM after depletion of PDE4D. Critically, compared with nontargeting control cells, shBIM-expressing cells were significantly (P = 0.029) resistant to shPDE4D-induced apoptosis.
PDE4D-Depletion Inhibits MITF Expression in Melanoma. The mechanisms shown above, however, were not responsible for apoptosis in PDE4D-depleted melanoma cells. These PDE4D silenced cells did not have induction of BIM, and silencing BIM could not rescue melanoma cells from apoptosis. Notably, silencing PDE4D in melanoma cells (A375 and M368) was associated with a marked decrease expression of MITF, a well-characterized lineage-specific oncogene in melanoma (Fig. 5C) . MITF is crucial for the survival of melanoma cells, as evidenced by the findings that MITF depletion leads to a massive cell death (16, 17) . We noticed that MITF-decreased cells also had increased cleaved PARP and caspase-9 and decreased level of B-cell lymphoma-extra large (BCL-XL) (Fig. 5C ). In agreement with the reports that MITF activated cyclin-dependent kinase inhibitor 1 (p21 Cip1 ) expression (18), we found that p21
Cip1 protein was markedly decreased upon PDE4D knockdown (Fig. 5C ). We further found that MITF mRNA level was down-regulated in PDE4D-depleted cells (Fig.  5D) . Notably, in silico analysis revealed that in two melanoma gene expression databases (19, 20) , mRNA expression of PDE4D and MITF was significantly correlated with each other (Fig. 5 E  and F) . Furthermore, Fig. 5E also showed that the expression of both PDE4D and MITF increased when comparing level in normal skin, benign melanocytes nevus, and cutaneous melanomas. These results indicate that in melanoma, PDE4D might positively (PDE4D diploid, 2N ). The specificity of the RT-PCR was confirmed by shRNA-mediated depletion as well as direct sequencing (SI Appendix, Fig. S3D ). Arrows indicate where two gels were spliced. (B) Various cell lines either with (homozygous deleted, HD) or without (2N) PDE4D internal microdeletions were subjected to Western blot (WB) analysis with antibodies against the carboxy terminus of PDE4D, which detect all known human PDE4D isoforms. GAPDH was used as a loading control. Arrows label the bands, which disappeared upon shRNA knockdown of PDE4D, indicating they were protein products of PDE4D transcripts. The specificity of WB was confirmed by shRNA-mediated knockdown experiments (Fig. 4A ). (C) Plots showing the correlation between PDE4D mRNA level and its DNA copy number. Matched mRNA and DNA copy number data were from TCGA projects (30): breast carcinoma (451 cases), head and neck squamous cell carcinoma (288 cases), lung squamous cell carcinoma (121 cases), and lung adenocarcinoma (112 cases). Kaplan-Meier plots and P values based on a log-rank test are indicated for the comparison of cases with high levels (defined as: > mean in endometrium; > mean + 2 SD in HNSCC) versus low levels (defined as: < mean in endometrium; < mean + 2 SD in HNSCC) of PDE4D mRNA. Survival data were generated from TCGA endometrium carcinoma and head and neck squamous cell carcinoma (HNSCC) projects (30) .
regulate MITF expression and thus play a vital role in cell survival and viability.
PDE4D2 Promoted Melanoma Proliferation Both in Vitro and in Vivo.
To address further the PDE4D contribution to the neoplastic phenotype, we ectopically expressed and studied two PDE4D transcript isoforms, namely PDE4D2 and PDE4D3. The expression of PDE4D3 did not result in appreciable change in either cell proliferation or resistance to apoptosis (SI Appendix, Fig. S7 A  and B) . In contrast, ectopic expression of PDE4D2 significantly enhanced the proliferation of A375 and gastric cancer cells (HGC-27) (Fig. 6 A and B) but not ovarian cancer cell line (Caov2) and Ishikawa cells in vitro (SI Appendix, Fig. S7 C and D) . More importantly, A375 cells with forced expression of PDE4D2 resulted in the development of significantly (P < 0.002) larger tumors compared with the GFP-control cells (Fig. 6 C and D) .
Specific PDE4D Inhibitor Treatment Preferentially Suppressed the
Proliferation of Malignant Cells. The above observations prompted us to test the strategy of PDE4D suppression as a therapeutic approach in cancer treatment. We examined the antineoplastic activity of a unique specific PDE4D inhibitor (26B) (Fig. 6E) . The inhibitor 26B is a highly selective PDE4D inhibitor with a 75-fold lower activity against the PDE4A, B, and C subtypes. It also exhibits 18,000-fold decreased potency against other PDE family members (21) . We first examined and determined that 26B significantly suppressed PDE4D activity at around 1 μM (SI Appendix, Fig. S8D ). We further found that exposure of a panel of human tumor cells of diverse origins to compound 26B caused dramatic apoptosis and growth inhibition (Fig. 6F) . To rule out off-targets effects, we codepleted other PDE4 family members through shRNA-mediated knockdown. As shown in SI Appendix, Fig. S8 B-G, 26B suppressed PDE4D-dependent malignant cell growth through inhibiting PDE4D; on the other hand, in PDE4D-independent cancer cells (e.g., A2008), 26B caused growth retardation by targeting other PDE4 family members. Treatment with the compound also elevated BIM expression and downregulated MITF protein levels, which paralleled the shPDE4D-induced molecular changes (Fig. 6G) . Importantly, treatment with 26B did not result in cell death or growth retardation in MCF-10A nontransformed breast cells (Fig. 6H) . These results Subsequently, cells were subjected to WB analysis with indicated antibodies or FCM analysis by Annexin V-FITC/propidium iodide staining (E). Exogenous PDE4D2 (Ex) migrates to approximately 69KD and the major endogenous PDE4D (En) in MB-231 migrates to about 95KD on SDS-PAGE. **, P < 0.01; *, P < 0.05; N.S., not significant. Apoptosis and proliferation data represent mean ± SD of three independent experiments. 2N, PDE4D diploid; HD, PDE4D homozygous deleted. . Each dot represents the expression level of PDE4D (x axis) and MITF (y axis) of a given sample. Pearson P and R values were calculated with r script by analyzing of the raw microarray data. Data represent mean ± SD of three independent experiments. **P < 0.01; *P < 0.05. UD, undetectable.
suggest that compound 26B has potential therapeutic use in neoplastic diseases.
Discussion
Cancer cells typically exhibit loss of genomic materials containing recessive cancer genes. On the other hand, due to the instability of the cancer genome, genes not implicated in cancer development (passengers) also are deleted. In the present study, we report a unique finding that homozygous deletions also occur in a locus involving a tumor-promoting gene, PDE4D. One of the most important data supporting the conclusion that PDE4D functions similar to an oncogene rather than a recessive cancer gene were derived from our demonstrations that PDE4D suppression triggered apoptotic cell death and growth retardation in cancer cells, but not in nonmalignant cells. The prosurvival/ growth roles of PDE4D were observed in a panel of cancer cells from different tissue types, indicating its broad tumor-promoting activity.
We deep sequenced all of the PDE4D coding regions from the PDE4D-microdeleted (including TNT-18) as well as a number of PDE4D-unaffacted patient samples of diverse origins and could find no nonsynonymous somatic mutations. We also resequenced 40 different gastric cancer cell lines, consisting of both PDE4D-microdeleted and PDE4D-unaffected ones, and found two synonymous single nucleotide variations (SNVs) and one nonsynonymous SNV (SI Appendix, Fig. S9A ). Polyphen (http:// genetics.bwh.harvard.edu/pph2/) predicted that Phe to Tyr at ninth amino acid heterozygous SNV is 100% "healthy" for the PDE4D protein, indicating that it was unlikely to result in inactivation or loss of function of PDE4D.
Another observation suggesting that PDE4D might be a tumor-promoting factor was the up-regulation of its protein in tumor cells compared with adjacent normal tissues. We reasoned that PDE4D protein elevation in cancers was not caused by genome microdeletions but due to other mechanisms based on the following observations: (i) The deletion did not lead to either enhanced or reduced mRNA expression ( Fig. 2A) . In addition, the PDE4D protein levels were comparable between cells either with or without PDE4D internal deletions (Fig. 2B and SI Appendix , Fig. S3C); (ii) Compared with the frequency of homozygous deletions (∼4%), the overexpression of PDE4D protein is much more common. For instance, 6 of 10 gastric tumors (60%) expressed an elevated level of PDE4D, whereas the normal tissues did not express detectable PDE4D (SI Appendix, Table S5 ).
In-depth analysis showed that internal microdeletions of PDE4D affected regions in the first eight exons (SI Appendix, Fig.  S3A ). These exons encode upstream conserved region 1 (UCR1) and UCR2, which are critical for the control of PDE4D catalytic activity. Specifically, UCR1 module determines the functional outcome of direct ERK phosphorylation. In the presence of UCR1, ERK phosphorylation leads to suppression of PDE4D catalytic activity; whereas in the absence of UCR1, the functional consequence of this modification is activation (22) (23) (24) . On the other hand, UCR2 bears an autoinhibitory property against PDE4D catalytic activity (25) (26) (27) . Given that ERK hyperactivation is common across human cancers, loss of UCR1/UCR2 caused by the genomic microdeletions will conceivably lead to PDE4D activation. Importantly, we constructed crystal 3D structural models and showed that UCR1 (fully) and UCR2 (partially) cover the ligand binding site of the PDE4D catalytic domain (SI Appendix, Fig. S9B ). By doing so, both UCR1 and UCR2 are likely to form complexes with the PDE4D catalytic domain before the substrate cAMP enters the active site, thus preventing the catalyzing process. Furthermore, we ectopically expressed both PDE4D long form (PDE4D3, which contains both UCR1 and UCR2) and the super short form (PDE4D2, which does not have either a functional UCR1 or UCR2) and showed that only PDE4D2 promoted cancer cell growth, indicating that PDE4D super short form has stronger oncogenic activity than the long form.
Taken together, genomic microdeletions of PDE4D, which either partially or fully remove UCR1 and/or UCR2 domains, probably lead to elevation of PDE4D catalytic activity. This, in turn, suppresses cellular cAMP concentrations. As shown by multiple studies, lower cAMP level is one of the favorable factors for the survival and proliferation of cancer cells (6-10, 28, 29) . Therefore, the truncated PDE4D protein produced by the genomic deletions might contribute a growth advantage to the cancer cells. Combined with our findings that inhibition of PDE4D preferentially induced apoptotic cell death in transformed cells with a minimal effect on nonmalignant cells, we propose that targeting this enzyme is a potential therapeutic approach.
Materials and Methods
Tumor Samples and SNP-Chip Analysis. Genomic abnormalities of tumor DNA from 55 TNBCs were studied by SNP-Chip. The sources of tumor specimens are listed in SI Appendix, SI Methods. The clinical-pathological parameters are shown in SI Appendix, Table S7 . SNP-Chips for human 250K arrays were used (SNP-Chip, Affymetrix). Partek Genomics Suite 6.6 was used for analysis of /OD 595 DMSO of each cell line and expressed as a percentage of proliferation in DMSO control. (G) Various cells were treated with either DMSO or 26B for 48 h and subjected to either WB analysis or (H) FCM analysis by staining with annexin V-FITC/propidium. *P < 0.05; **P < 0.01; ***P < 0.001; NS, not significant. Data represent the mean ± SD of three independent experiments. SNP-chip data from our in-house dataset as well as the ones from Wellcome Trust Sanger Institute Cancer Genome Project.
Cell Culture and Chemicals. All of the human cancer cell lines were maintained at 37°C in a 5% (vol/vol) CO 2 air humidified incubator in ATCC-suggested conditions. Melanoma cells (A375 and M368) were generously provided by Antoni Ribas (University of California, Los Angeles). Ovary cancer cells (Caov2 and A2008) and lung cancer cells H838 were kindly provided by Ruby Huang and Jizhong Shi (Cancer Science Institute of Singapore). Compound 26B was provided by Craig J. Thomas (Chemical Genomics Center, National Institutes of Health, Bethesda, MD). Other chemicals used were of the highest grade available from Sigma-Aldrich.
Statistical Analysis. The correlation between the expression levels of PDE4D and MITF was analyzed using the Pearson's R correlation test. The log-rank test was used for Kaplan-Meier survival analysis. Other statistical analyses were conducted using the two-tailed Student t test. Statistical significance was defined at P < 0.05. 
